Italian study tracks Real-Life results of new lung cancer combo therapy

NCT ID NCT07190677

Recruiting now Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 30 times

Summary

This study is collecting information from 300 people in Italy with advanced non-small cell lung cancer who are receiving a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment. The goal is to see how well this treatment works in everyday medical practice, not just in controlled trials. Researchers will track how long people live and how long their cancer stays under control, as well as any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fondazione IRCCS Policlinico San Matteo
RECRUITING

Pavia, Lombardy, 27100, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER METASTATIC NON-SMALL CELL LUNG CANCER METASTATIC